HLB Panagene Co., Ltd. (KOSDAQ:046210)
1,790.00
-78.00 (-4.18%)
At close: Jan 29, 2026
HLB Panagene Revenue
HLB Panagene had revenue of 3.64B KRW in the quarter ending September 30, 2025, a decrease of -5.61%. This brings the company's revenue in the last twelve months to 14.29B, up 15.43% year-over-year. In the year 2024, HLB Panagene had annual revenue of 13.20B with 7.71% growth.
Revenue (ttm)
14.29B
Revenue Growth
+15.43%
P/S Ratio
5.33
Revenue / Employee
174.26M
Employees
82
Market Cap
76.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13.20B | 944.89M | 7.71% |
| Dec 31, 2023 | 12.25B | -16.39B | -57.22% |
| Dec 31, 2012 | 28.64B | -12.81B | -30.91% |
| Dec 31, 2011 | 41.45B | 7.41B | 21.77% |
| Dec 31, 2010 | 34.04B | 1.70B | 5.26% |
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Medical Science | 111.12B |
| Seoulin Bioscience | 76.74B |
| Dx & Vx | 29.47B |
| Cytogen | 25.09B |
| Protia | 13.52B |
| 3billion | 9.78B |
| GENINUS | 8.81B |
| Median Diagnostics | 7.86B |